[Biotherapy of auto-immune diseases : past, present and future perspectives].

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Presse medicale

• Publication date

  2009-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.lpm.2008.12.023PMID 19303737
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial.

  2008cited by this paper
• Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study.

  2008cited by this paper
• Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

  2008cited by this paper
• Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study.

  2008cited by this paper
• The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemic-onset juvenile idiopathic arthritis.

  2008cited by this paper
• Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes.

  2008cited by this paper
• [Systemic lupus erythematosus: future therapeutic avenues].

  2008cited by this paper
• Emerging therapeutics for rheumatoid arthritis.

  2008cited by this paper
• Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis

  2008cited by this paper
• Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.

  2008cited by this paper
• Durable complete responses from therapy with combined epratuzumab and rituximab

  2008cited by this paper
• Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

  2008cited by this paper
• Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies.

  2008cited by this paper
• Anakinra improves sensory deafness in a Japanese patient with Muckle-Wells syndrome, possibly by inhibiting the cryopyrin inflammasome.

  2008cited by this paper
• Lupus systémique : les traitements du futur

  2008cited by this paper
• Antibody Engineering Principles and Applications

  2008cited by this paper
• Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody.

  2008cited by this paper
• Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study.

  2008cited by this paper
• Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.

  2008cited by this paper
• First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.

  2008cited by this paper
• Treatment of patients with the hypereosinophilic syndrome with mepolizumab.

  2008cited by this paper
• Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls

  2007cited by this paper
• Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial.

  2007cited by this paper
• A single cycle of rituximab for the treatment of severe pemphigus.

  2007cited by this paper
• Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H)

  2007cited by this paper
• Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.

  2007cited by this paper
• Assessment of rituximab’s immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results

  2007cited by this paper
• Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis.

  2007cited by this paper
• A pilot trial of rituximab in the treatment of patients with dermatomyositis.

  2007cited by this paper
• Long-term effects of combination treatment with fludarabine and low-dose pulse cyclophosphamide in patients with lupus nephritis.

  2007cited by this paper
• Rituximab for refractory polymyositis: an open-label prospective study.

  2007cited by this paper
• Improvement of Sjögren's syndrome after two infusions of rituximab (anti-CD20).

  2007cited by this paper
• Certolizumab pegol for the treatment of Crohn's disease.

  2007cited by this paper
• Maintenance therapy with certolizumab pegol for Crohn's disease.

  2007cited by this paper
• Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France

  2007cited by this paper
• The role of the innate immune response in autoimmune disease.

  2007cited by this paper
• Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.

  2006cited by this paper
• Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab.

  2006cited by this paper
• B cell depletion therapy in systemic rheumatic diseases: different strokes for different folks?

  2006cited by this paper
• Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus

  2006cited by this paper
• Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial.

  2006cited by this paper
• Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study

  2006cited by this paper
• Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system

  2006cited by this paper
• Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.

  2006cited by this paper
• Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study.

  2006cited by this paper
• Blockade of chemokine signaling in patients with multiple sclerosis

  2006cited by this paper
• A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

  2006cited by this paper
• Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis.

  2005cited by this paper
• TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs.

  2005cited by this paper
• Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade

  2005cited by this paper
• Beneficial response to anakinra and thalidomide in Schnitzler’s syndrome

  2005cited by this paper
• Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

  2005cited by this paper
• Amelioration of rat adjuvant-induced arthritis by Met-RANTES.

  2005cited by this paper
• Rituximab in the treatment of dermatomyositis: an open-label pilot study.

  2005cited by this paper
• A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate

  2004cited by this paper
• Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist.

  2004cited by this paper
• Rheumatoid arthritis: direct and indirect costs.

  2004cited by this paper
• Treatment of Crohn’s disease with anti-IL-6 receptor antibody

  2004cited by this paper
• From the bench to the bedside: ways to improve rituximab efficacy.

  2004cited by this paper
• HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris.

  2003cited by this paper
• The role of interleukin-10 in systemic lupus erythematosus.

  2003cited by this paper
• A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis.

  2003cited by this paper
• Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig.

  2003cited by this paper
• Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial.

  2002cited by this paper
• Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial.

  2002cited by this paper
• Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome.

  2002cited by this paper
• Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.

  2002cited by this paper
• Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

  2002cited by this paper
• Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes.

  2001cited by this paper
• Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus1

  2001cited by this paper
• Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

  2001cited by this paper
• Reply to Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand

  2000cited by this paper
• Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus.

  2000cited by this paper
• Chemokines: a new classification system and their role in immunity.

  2000cited by this paper
• Interleukin-10 signaling blocks inhibitor of kappaB kinase activity and nuclear factor kappaB DNA binding.

  1999cited by this paper
• Interleukin-10 Signaling Blocks Inhibitor of κB Kinase Activity and Nuclear Factor κB DNA Binding*

  1999cited by this paper
• Anti-CD40 ligand antibody treatment of SNF1 mice with established nephritis: preservation of kidney function.

  1998cited by this paper
• Peripheral blood lymphocytes in SLE--hyperexpression of CD154 on T and B lymphocytes and increased number of double negative T cells.

  1998cited by this paper
• Immunohistologic analysis of renal CD40 and CD40L expression in lupus nephritis and other glomerulonephritides.

  1997cited by this paper
• CD22 regulates thymus-independent responses and the lifespan of B cells

  1996cited by this paper
• Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice. Response correlates with the absence of an anti-antibody response.

  1996cited by this paper
• Traffic signals on endothelium for lymphocyte recirculation and leukocyte emigration.

  1995cited by this paper
• Research article Open Access Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study

  year unknowncited by this paper

• Le psoriasis : physiopathologie, traitements et conseils à l’officine en 2016

  2016cites this paper
• [Placental immunoglobulin transfer].

  2012cites this paper
• [Biotherapies to treat necrotizing vasculitis].

  2010cites this paper
• Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls.

  2010cites this paper
• Conception et évaluation de la faisabilité d'un outil pédagogique d'éducation thérapeutique pour les patients atteints de rhumatisme inflammatoire chronique traités par biothérapie

  2010cites this paper
• [Systemic lupus and biotherapy: 2010 update].

  2010cites this paper
• [Biotherapies: toward a second revolution?].

  2009cites this paper